Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J. Sevillano D, et al. Among authors: carcas a. J Antimicrob Chemother. 2004 Dec;54(6):1148-51. doi: 10.1093/jac/dkh463. Epub 2004 Oct 15. J Antimicrob Chemother. 2004. PMID: 15489246
Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.
Gracia M, Martínez-Marín C, Huelves L, Giménez MJ, Aguilar L, Carcas A, Ponte C, Soriano F. Gracia M, et al. Among authors: carcas a. Antimicrob Agents Chemother. 2005 Mar;49(3):996-1001. doi: 10.1128/AAC.49.3.996-1001.2005. Antimicrob Agents Chemother. 2005. PMID: 15728894 Free PMC article.
Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J. Alou L, et al. Among authors: carcas a. J Antimicrob Chemother. 2005 May;55(5):742-7. doi: 10.1093/jac/dki071. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761068 Clinical Trial.
Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
Ponte C, Gracia M, Giménez MJ, Aguilar L, Maín CM, Carpintero Y, Huelves L, Carcas A, del Prado G, Soriano F. Ponte C, et al. Among authors: carcas a. Clin Ther. 2005 Jul;27(7):1043-9. doi: 10.1016/j.clinthera.2005.07.001. Clin Ther. 2005. PMID: 16154483 Clinical Trial.
Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains.
Carcas AJ, Sevillano D, González N, Alou L, Gómez-Gil R, Muñoz M, Llanos L, Sanchez-Villanueva RJ, Gonzalez-Parra E, Giménez MJ, Aguilar L. Carcas AJ, et al. J Glob Antimicrob Resist. 2019 Dec;19:241-251. doi: 10.1016/j.jgar.2019.05.027. Epub 2019 Jun 6. J Glob Antimicrob Resist. 2019. PMID: 31176754
Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL; PGX-ACE Spanish Investigators Group. Carcas AJ, et al. Trials. 2012 Dec 13;13:239. doi: 10.1186/1745-6215-13-239. Trials. 2012. PMID: 23237631 Free PMC article. Clinical Trial.
109 results